PMV Pharmaceuticals, Inc. (PMVP) stock
PMVPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.22+0.03 (+2.52%)
Close on Nov 17, 2026Market cap $65.22MP/E –Yield –
PMV Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
PMV Pharmaceuticals's total assets was $82.07M at Jun 30, 2026. For fiscal 2025 it was $116.56M, down 39.1% from the year before. The highest annual figure on record is $365.53M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.56M | -39.1% |
| FY2024 | Dec 31, 2024 | $191.29M | -24.1% |
| FY2023 | Dec 31, 2023 | $252.15M | -6.7% |
| FY2022 | Dec 31, 2022 | $270.31M | -18.5% |
| FY2021 | Dec 31, 2021 | $331.57M | -9.3% |
| FY2020 | Dec 31, 2020 | $365.53M | +254.8% |
| FY2019 | Dec 31, 2019 | $103.03M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $82.07M | -46.3% |
| Q1 FY2026 | Mar 31, 2026 | $96.56M | -43.4% |
| Q4 FY2025 | Dec 31, 2025 | $116.56M | -39.1% |
| Q3 FY2025 | Sep 30, 2025 | $133.84M | -40.1% |
| Q2 FY2025 | Jun 30, 2025 | $152.86M | -35.7% |
| Q1 FY2025 | Mar 31, 2025 | $170.61M | -28.0% |
| Q4 FY2024 | Dec 31, 2024 | $191.29M | -24.1% |
| Q3 FY2024 | Sep 30, 2024 | $223.50M | -14.4% |
| Q2 FY2024 | Jun 30, 2024 | $237.54M | -1.9% |
| Q1 FY2024 | Mar 31, 2024 | $236.88M | -6.7% |
| Q4 FY2023 | Dec 31, 2023 | $252.15M | -6.7% |
| Q3 FY2023 | Sep 30, 2023 | $261.03M | -8.4% |
| Q2 FY2023 | Jun 30, 2023 | $242.22M | -19.4% |
| Q1 FY2023 | Mar 31, 2023 | $253.96M | -19.4% |
| Q4 FY2022 | Dec 31, 2022 | $270.31M | -18.5% |
| Q3 FY2022 | Sep 30, 2022 | $284.98M | -17.2% |
| Q2 FY2022 | Jun 30, 2022 | $300.56M | -15.6% |
| Q1 FY2022 | Mar 31, 2022 | $315.01M | -11.1% |
| Q4 FY2021 | Dec 31, 2021 | $331.57M | -9.3% |
| Q3 FY2021 | Sep 30, 2021 | $344.18M | -8.1% |
| Q2 FY2021 | Jun 30, 2021 | $355.91M | +245.4% |
| Q1 FY2021 | Mar 31, 2021 | $354.39M | – |
| Q4 FY2020 | Dec 31, 2020 | $365.53M | – |
| Q3 FY2020 | Sep 30, 2020 | $374.45M | – |
| Q4 FY2019 | Dec 31, 2019 | $103.03M | – |
See a number that looks wrong?